phase readout
saveNCT07480681: Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
NOT_YET_RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: Shanghai Henlius Biotech. Phase: PHASE1. Conditions: Advanced/Metastatic Solid Tumors
view source ↗
comments(0)
5-min edit window · permanent after that